DrugsControl Media Services
DrugsControl.org

News Detail

SEC refuses local clinical trial waiver for Roche's cancer drug Tecentriq (25-01-2024)

New Delhi, 25 Jan 2024: The Subject Expert Committee (SEC) that advises the national drug regulator on approvals for drugs and clinical trials, among other matters, has refused a proposal from Roche Products (India) for approval of cancer drug Tecentriq through subcutaneous route......
View Details

Source : Pharmabiz
SEC Tecentriq Atezolizumab clinical trial waiver NSCLC HCC Subject Expert Committee Roche Products (India) PD-(L) cancer Enhanze Halozyme Therapeutics NSCLC SCLC hepatocellular carcinoma HCC

Related News